CFO

NattoPharma ASA is looking for an ambitious CFO with a commercial mindset with strategic focus to further develop the financial platform of the company. The CFO will play a key role in the management team, working closely with the CEO, ensuring that NattoPharma is delivering according to its strategy and its business ambitions.

The new CFO will be a driving force to the financial and economic development of NattoPharma ASA, and will be responsible for the financial monitoring, control and reporting, and managing the financial forecasting and budgets. Based on a modern digitized platform, the CFO will build and strengthen all the financial processes, as well as the internal routines and policies of the business. NattoPharma is a growing company and the new CFO will have the possibility to participate in the company’s overall development, including supply chain improvements.

We believe you are an ambitious, operational and business oriented economist who sees the potential and opportunities that lie within the company and the market. You hold a Masters degree in Accounting/Finance, a minimum of 5 years relevant work-experience as controller, financial manager or CFO, and relevant experience from a listed company. Profound knowledge of and experience with Norwegian tax system and laws is required. International experience, as well as from a matrix organization, is an advantage.

NattoPharma offers a dynamic environment within a fast-growing industry where you can expect to be able to put your fingerprint on the next step in the company’s development. The position will be reporting to the CEO and the workplace will be Lysaker, Oslo.

Questions can be directed to Visindi; Monica Strysse, mobile + 47 971 00 769 or Magne Amundsen, mobile +47 916 56 101.

Om selskapet

NattoPharma ASA is a Norwegian nutraceutical company, established in 2004 and listed on the Oslo Stock Exchange. The company is world leader in vitamin K2 research and development and is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented vitamin K2 as menaquinone-7 (MK-7) with international patents granted and pending. NattoPharma has a multi-year R&D program to substantiate and discover the health benefits of Vitamin K2 for applications in the marketplace for functional food and dietary supplements, in addition to exclusive access to the research efforts of its pharmaceutical arm, Kaydence Pharma AS (est. 2017), outside of the pharmaceutical domain. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc. in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. The Lysaker corporate office houses 8 employees.

--------------------------------------------------------
Vennligst referer til DN.no i din søknad.